Abstract
Schochl and co-authors have described a 5-year retrospective study that outlines a novel, important and controversial transfusion concept in seriously injured trauma patients. Traditionally, clinicians have been taught to use a serial approach, resuscitating hypovolemic trauma patients with a form of crystalloid or colloid, followed by red blood cells (RBCs), then fresh frozen plasma (FFP), and lastly platelets. The data supporting this widely accepted approach are remarkably weak. Conversely, Schochl and colleagues, in an innovative, retrospective study, describe the use of fibrinogen concentrate, plasma complex concentrate, RBCs, FFP, and platelets driven by a thromboelastometry-based algorithm. Finally, it appears that transfusion therapy is becoming driven by physiology.
Highlights
Schochl and co-authors have described a 5-year retrospective study that outlines a novel, important and controversial transfusion concept in seriously injured trauma patients
The usual concerns apply as there is no control group, the data supporting the thromboelastometry goal-directed algorithm are not presented, and the risks of using and combining fibrinogen concentrates and plasma complex concentrates (PCCs) in trauma patients are unknown
With regards to the study by Schochl and colleagues, I am concerned with the comparison of mortality rates in the small numbers of seriously injured patients collected over 5 years to that predicted by the trauma injury severity score (TRISS) and by the revised injury severity
Summary
Schochl and co-authors have described a 5-year retrospective study that outlines a novel, important and controversial transfusion concept in seriously injured trauma patients. With regards to the study by Schochl and colleagues, I am concerned with the comparison of mortality rates in the small numbers of seriously injured patients collected over 5 years to that predicted by the trauma injury severity score (TRISS) and by the revised injury severity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
